Phase 2 · NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT05936151
- Indication
- Overweight or Obesity, CKD, Type 2 Diabetes
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 146
- Status
- Completed
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 42 sites · Canada, Italy, Spain, United Kingdom, United States
- Study start
- 20 Jul 2023
- Primary completion
- 1 Oct 2025
- Study completion
- 21 Oct 2025
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 25 Nov 2025
Endpoints
Primary
Change from Baseline in Glomerular Filtration Rate (mGFR)
Secondary
Change from Baseline in Urine Albumin-to-Creatinine Ratio (UACR); Change from Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa); Change from Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR); Change from Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit; Change from Baseline in in Mean Arterial Flow (MAF); Change from Baseline in Renal Artery Resistive Index (RARI); Change from Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) and End-diastolic Velocity (ESV); Change from Baseline in Global Renal Perfusion (MRI); Change from Baseline in Total Renal Parenchyma Volume (MRI); Change from Baseline in Renal Cortex Volume (MRI); Change from Baseline in Renal Cortex T1 (ms) (MRI); Change from Baseline in Medulla T1 (ms) (MRI); Change from Baseline in Renal Cortex R2 (BOLD MRI); Change from Baseline in Medulla R2; Change from Baseline in Body Weight; Change from Baseline in 24-hr Urinary Albumin Excretion (UAE); Change from Baseline in Change in 24-hour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h))
Registry monitoring
Latest Trial Changes
| Field | Change | Detected | Source |
|---|---|---|---|
| Recruitment status | Recruiting→Completed | 4 Sept 2026 | ClinicalTrials.gov |
| Enrolment | 980→146 | 4 Sept 2026 | ClinicalTrials.gov |
| Phase | Phase 3→Phase 2 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary completion date | 2027-06-30→2025-10-01 | 4 Sept 2026 | ClinicalTrials.gov |
| Study completion date | Not yet confirmed→2025-10-21 | 4 Sept 2026 | ClinicalTrials.gov |